The tumors treated with anti-FGL2 antibody were also found to have lower CD44 expression and higher Olig2 expression than the control group, indirectly demonstrating that high expression of FGL2 is associated with the mesenchymal subtype of glioma. The gene discussed is FGL2; the disease is central nervous system cancer.